{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:05:11Z","timestamp":1780571111865,"version":"3.54.1"},"reference-count":52,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2023.12214","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T12:31:17Z","timestamp":1695213077000},"source":"Crossref","is-referenced-by-count":4,"title":["\u0395fficacy and safety of vortioxetine (Lu AA21004) in the treatment of adult patients with major depressive disorder: A systematic review and a meta\u2011analysis of randomized controlled trials"],"prefix":"10.3892","volume":"26","author":[{"given":"Shan","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Chengdu Second People's Hospital, Chengdu, Sichuan 618000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yaan People's Hospital, Yaan, Sichuan 625000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deming","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yaan People's Hospital, Yaan, Sichuan 625000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"key20231026123155_b1-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0165-0327(14)70004-7","article-title":"Differential diagnosis of bipolar disorder and major depressive disorder","volume":"169 (Suppl 1)","author":"Hirschfeld","year":"2014","journal-title":"J Affect Disord"},{"key":"key20231026123155_b2-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental Disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"DE Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"key20231026123155_b3-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.4088\/JCP.12r07967","article-title":"The effect of prenatal antidepressant exposure on neonatal adaptation: A systematic review and meta-analysis","volume":"74","author":"Grigoriadis","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"key20231026123155_b4-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s40265-013-0116-1","article-title":"Levomilnacipran extended-release: First global approve","volume":"73","author":"Hair","year":"2013","journal-title":"Drugs"},{"key":"key20231026123155_b5-ETM-26-5-12214","first-page":"S4","article-title":"Comorbidity of mental and physical disorders: A main challenge to medicine in the 21st century","volume":"25 (Suppl 1)","author":"Sartorius","year":"2013","journal-title":"Psychiatr Danub"},{"key":"key20231026123155_b6-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2147\/NDT.S54710","article-title":"Levomilnacipran: A new drug for treatment of major depressive disorder","volume":"34","author":"He","year":"2015","journal-title":"Chin J New Drugs Clin Rem"},{"key":"key20231026123155_b7-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J Med Chem"},{"key":"key20231026123155_b8-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.euroneuro.2012.04.006","article-title":"Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters a rat microdialysis and electrophysiology study","volume":"23","author":"Pehrson","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"key20231026123155_b9-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40265-013-0161-9","article-title":"Vortioxetine: First global approval","volume":"74","author":"Gibb","year":"2014","journal-title":"Drugs"},{"key":"key20231026123155_b10-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1177\/0269881112441866","article-title":"A randomized clinical study of Lu AA21004 in theprevention of relapse in patients with major depressive disorder","volume":"26","author":"Boulenger","year":"2012","journal-title":"J Psychopharmacol"},{"key":"key20231026123155_b11-ETM-26-5-12214"},{"key":"key20231026123155_b12-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40261-016-0396-9","article-title":"Vortioxetine versus duloxetine in the treatment of patients with major depressive disorder: A Meta-analysis of randomized controlled trials","volume":"36","author":"Li","year":"2016","journal-title":"Clin Drug Investig"},{"key":"key20231026123155_b13-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1503\/jpn.140120","article-title":"Vortioxetine: A meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder","volume":"40","author":"Pae","year":"2015","journal-title":"J Psychiatry Neurosci"},{"key":"key20231026123155_b14-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/0269881116628440","article-title":"The safety and tolerability of vortioxetine: Analysis of data from randomized Placebo-controlledtrials and open-label extension studies","volume":"30","author":"Baldwin","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"263","key":"key20231026123155_b15-ETM-26-5-12214","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0663-8","article-title":"Evaluations of the uptake and impact of the preferred reporting items for systematic reviews and Meta-analysis (PRISMA) statement and extensions: A scoping review","volume":"6","author":"Page","year":"2017","journal-title":"Syst Rev"},{"issue":"e4057","key":"key20231026123155_b16-ETM-26-5-12214","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004057","article-title":"Systematic review and meta-analysis of sutures coated with triclosan for the prevention of surgical site infection after elective colorectal surgery according to the PRISMA statement","volume":"95","author":"Sandini","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"e83138","key":"key20231026123155_b17-ETM-26-5-12214","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083138","article-title":"Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses","volume":"8","author":"Panic","year":"2013","journal-title":"PLoS One"},{"key":"key20231026123155_b18-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/JCP.0000000000000128","article-title":"Effect of methylphenidate on neurocognitive test battery: An evaluation according to the diagnostic and statistical manual of mental disorders, fourth edition, subtypes","volume":"34","author":"Durak","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"key20231026123155_b19-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/j.1743-6109.2007.00557.x","article-title":"The Diagnostic and statistical manual of mental distal disorders, Fouth edition, text revision as an appropriate diagnostic for premature ejaculation","volume":"4","author":"Shabsigh","year":"2007","journal-title":"J Sex Med"},{"key":"key20231026123155_b20-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S2045796017000683","article-title":"Frequency of use of the international classification of diseases ICD-10 diagnostic categories for mental and behavioural disorders across world regions","volume":"11","author":"Faiad","year":"2017","journal-title":"Epidemiol Psychiatr Sci"},{"key":"key20231026123155_b21-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00788743","article-title":"The ICD-10 symptom checklist: A companion to the ICD-10 classification of mental and behavioural disorders","volume":"28","author":"Janca","year":"1993","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"key20231026123155_b22-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/j.2051-5545.2011.tb00022.x","article-title":"A conceptual framework for the revision of the ICD-10 classification of mental and behavioural disorders","volume":"10","year":"2011","journal-title":"World Psychiatry"},{"issue":"178","key":"key20231026123155_b23-ETM-26-5-12214","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-178","article-title":"Use of non-parametric item response theory to develop a shortened version of the Positive and Negative Syndrome Scale (PANSS)","volume":"11","author":"Khan","year":"2011","journal-title":"BMC Psychiatry"},{"key":"key20231026123155_b24-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"219","DOI":"10.20882\/adicciones.965","article-title":"The efficacy of motivational intervention and cognitive-behavioral therapy for pathological gambling","volume":"30","author":"Garcia-Caballero","year":"2018","journal-title":"Adicciones"},{"key":"key20231026123155_b25-ETM-26-5-12214","first-page":"1","article-title":"Psychotherapy for Major depressive disorder and generalized anxiety disorder: A health technology assessment","volume":"17","year":"2017","journal-title":"Ont Health Technol Assess Ser"},{"key":"key20231026123155_b26-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/hup.989","article-title":"A direct comparison of effect sizes from the clinical global impression-improvement scale to effect sizes from other rating scales in controlled trials of adult social anxiety disorder","volume":"24","author":"Hedges","year":"2009","journal-title":"Hum Psychopharmacol"},{"key":"key20231026123155_b27-ETM-26-5-12214","author":"Higgins"},{"key":"key20231026123155_b28-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12888-014-0276-x","article-title":"Vortioxetine in the treatment of adult patients with major depressive disorder: A meta-analysis of randomized double-blind controlled trials","volume":"14","author":"Berhan","year":"2014","journal-title":"BMC Psychiatry"},{"key":"key20231026123155_b29-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1590\/1516-3180.2017.0310241017","article-title":"What do Cochrane systematic reviews say about probiotics as preventive interventions?","volume":"135","author":"Braga","year":"2017","journal-title":"Sao Paulo Med J"},{"key":"key20231026123155_b30-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4088\/JCP.11m07470","article-title":"A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder","volume":"73","author":"Henigsberg","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"key20231026123155_b31-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/pcn.12565","article-title":"Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg\/day vortioxetine in adults with major depressive disorder","volume":"72","author":"Nishimura","year":"2018","journal-title":"Psychiatry Clin Neurosci"},{"key":"key20231026123155_b32-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1017\/S1461145712000727","article-title":"A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder","volume":"16","author":"Jain","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"key20231026123155_b33-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1017\/S1461145714000546","article-title":"A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults","volume":"17","author":"McIntyre","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"key20231026123155_b34-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1185\/03007995.2012.761600","article-title":"A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder","volume":"29","author":"Mahableshwarkar","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"key20231026123155_b35-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.euroneuro.2011.11.008","article-title":"A randomised, double-blind, placebo controlled duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)","volume":"22","author":"Baldwin","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"key20231026123155_b36-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"key20231026123155_b37-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/npp.2015.52","article-title":"A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of efficacy of vortioxetine on cognitive function in major depressive disorder","volume":"40","author":"Mahableshwarkar","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"key20231026123155_b38-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/YIC.0000000000000018","article-title":"Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg\/day: A randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder","volume":"29","author":"Boulenger","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"key20231026123155_b39-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1007\/s00213-014-3839-0","article-title":"A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD","volume":"232","author":"Mahableshwarkar","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"key20231026123155_b40-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1017\/S1461145711001027","article-title":"A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder","volume":"15","author":"Alvarez","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"key20231026123155_b41-ETM-26-5-12214","first-page":"181","article-title":"Present situation and challenges of somatic syndromes in patients with serious mental illness","volume":"23","author":"Ma","year":"2014","journal-title":"Chin J Behav Med Brain Sci"},{"key":"key20231026123155_b42-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/PSY.0b013e3182280016","article-title":"Increased risks of acute organ dysfunction and mortality in intensive care unit patients with schizophrenia: A nationwide population-based study","volume":"73","author":"Shen","year":"2011","journal-title":"Psychosom Med"},{"key":"key20231026123155_b43-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"S6l","DOI":"10.1177\/1359786810382058","article-title":"Inequalities in healthcare provision for people with severe mental iuness","volume":"24 (4 Suppl)","author":"Lawrence","year":"2010","journal-title":"J Psychopharmacol"},{"key":"key20231026123155_b44-ETM-26-5-12214","first-page":"e483","article-title":"Cardiovascular preventive care for patients with serious mental illness","volume":"63","author":"Ritchie","year":"2017","journal-title":"Can Fam Physician"},{"key":"key20231026123155_b45-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s11606-008-0720-z","article-title":"Quality of care for cardiovascular disease-related conditions in patients with and without mental disorders","volume":"23","author":"Kilbourne","year":"2008","journal-title":"J Gen Intern Med"},{"key":"key20231026123155_b46-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ijo.2008.268","article-title":"Depression and anxiety among US adults: Associations with body mass index","volume":"33","author":"Zhao","year":"2009","journal-title":"Int J Obes (Lond)"},{"key":"key20231026123155_b47-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2015.12.012","article-title":"Vortioxetine promotes maturation of dendritic spines in vitro: A comparative study in hippocampal cultures","volume":"103","author":"Waller","year":"2016","journal-title":"Neuropharmacology"},{"key":"key20231026123155_b48-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.euroneuro.2015.12.018","article-title":"Vortioxetine promotes early changes in dendritic morphology compared to fluoxetine in rat hippocampus","volume":"26","author":"Chen","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"key20231026123155_b49-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.pnpbp.2016.03.001","article-title":"Histamine may contribute Tovortioxetine's procognitive effects; possibly through an orexigenic mechanism","volume":"68","author":"Smagin","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"21","key":"key20231026123155_b50-ETM-26-5-12214","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-015-0001-y","article-title":"The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: A systematic review and meta-analysis","volume":"4","author":"Meeker","year":"2015","journal-title":"Syst Rev"},{"issue":"922648","key":"key20231026123155_b51-ETM-26-5-12214","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.922648","article-title":"Systematic review and meta-analysis of vortioxetine for the treatment of major depressive disorder in adults","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Psychiatry"},{"key":"key20231026123155_b52-ETM-26-5-12214","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.euroneuro.2016.03.007","article-title":"A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults","volume":"26","author":"Thase","year":"2016","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T09:32:03Z","timestamp":1698312723000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2023.12214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,9,20]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2023.12214","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"article-number":"515"}}